1型糖尿病合并2型糖尿病相关TCF7L2遗传变异者含胰岛素胰岛丢失更轻
基于nPOD计划110例1型糖尿病供者,分析TCF7L2 rs7903146与残存含胰岛素胰岛百分比(ICI%)的关系。校正起病年龄、病程、BMI z评分、性别和非裔美国人种族后,携带T等位基因者高ICI%的可能性是无T等位基因者的2.93倍(95%CI 1.02, 8.47;p=0.047)。
要点
- TCF7L2 rs7903146 T等位基因携带者高ICI%(≥5)可能性为CC型者的2.93倍(95%CI 1.02, 8.47;p=0.047)。
- 高ICI%组较低于ICI%组起病年龄更大(15.3±6.9 vs 11.1±8岁,p=0.013),供者取材时病程更短(7.0±7.4 vs 18.5±14.3年,p<0.001)。
- 作者认为这些数据支持存在与2型糖尿病易感遗传因子相关的1型糖尿病内表型,其β细胞丢失较轻。
核心结论
- 总体而言,这些数据支持存在一种与2型糖尿病易感遗传因子相关的1型糖尿病内表型,该类别供者β细胞丢失较轻。
- 作者认为这些个体疾病发病机制可能包含与2型糖尿病相关的机制,或可解释部分个体对预防1型糖尿病或其进展的免疫治疗反应不佳。
- 作者提出若如此,针对同时存在的1型糖尿病和2型糖尿病相关因素的策略可能提高这些个体预防和治疗的成功率。
研究设计与样本
- 分析nPOD计划中110例1型糖尿病供者(起病年龄均值±SD 12.2±7.9岁,糖尿病病程均值±SD 15.3±13.7年,53%男性,80%非西班牙裔白人,12.7%非裔美国人,7.3%西班牙裔)。
- 使用残存β细胞数量数据,定量胰腺组织切片中含胰岛素阳性β细胞的胰岛,并表示为每个供者总胰岛数的百分比(ICI%均值±SD 9.8±21.5,范围0-92.2)。
主要发现
- 高ICI%(≥5)组30例(27%)与低ICI%(<5)组80例(73%)相比,起病年龄更大(15.3±6.9 vs 11.1±8岁,p=0.013)。
- 高ICI%组供者取材时糖尿病病程更短(7.0±7.4 vs 18.5±14.3年,p<0.001)。
- 高ICI%组非洲祖先评分更高(0.2±0.3 vs 0.1±0.2,p=0.043),欧洲祖先评分更低(0.7±0.3 vs 0.9±0.3,p=0.023)。
- 校正起病年龄(p=0.105)、糖尿病病程(p<0.001)、BMI z评分(p=0.145)、性别(p=0.351)和非裔美国人种族(p=0.053)后,携带TCF7L2 rs7903146 T等位基因(TC或TT,45.5%)的供者高ICI%的可能性是无T等位基因(CC)者的2.93倍(95%CI 1.02, 8.47;p=0.047)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: TCF7L2 variants are the strongest genetic risk factor for type 2 diabetes. In individuals with type 1 diabetes, these variants are associated with a higher C-peptide AUC, a lower glucose AUC during an OGTT, single autoantibody positivity near diagnosis, particularly in individuals older than 12 years of age, and a lower frequency of type 1 diabetes-associated HLA genotypes. Based on initial observations from clinical cohorts, we tested the hypothesis that type 2 diabetes-predisposing TCF7L2 genetic variants are associated with a higher percentage of residual insulin-containing cells (ICI%) in pancreases of donors with type 1 diabetes, by examining genomic data and pancreatic tissue samples from the Network for Pancreatic Organ donors with Diabetes (nPOD) programme. METHODS: We analysed nPOD donors with type 1 diabetes (n=110; mean±SD age at type 1 diabetes onset 12.2±7.9 years, mean±SD diabetes duration 15.3±13.7 years, 53% male, 80% non-Hispanic White, 12.7% African American, 7.3% Hispanic) using data pertaining to residual beta cell number; quantified islets containing insulin-positive beta cells in pancreatic tissue sections; and expressed these values as a percentage of the total number of islets from each donor (mean ± SD ICI% 9.8±21.5, range 0-92.2). RESULTS: Donors with a high ICI% (≥5) (n=30; 27%) vs a low ICI% (<5) (n=80; 73%) were older at onset (15.3±6.9 vs 11.1±8 years, p=0.013), had a shorter diabetes duration at donor tissue procurement (7.0±7.4 vs 18.5±14.3 years, p<0.001), a higher African ancestry score (0.2±0.3 vs 0.1±0.2, p=0.043) and a lower European ancestry score (0.7±0.3 vs 0.9±0.3, p=0.023). After adjustment for age of onset (p=0.105), diabetes duration (p<0.001), BMI z score (p=0.145), sex (p=0.351) and African American race (p=0.053), donors with the TCF7L2 rs7903146 T allele (TC or TT, 45.5%) were 2.93 times (95% CI 1.02, 8.47) more likely to have a high ICI% than those without it (CC) (p=0.047). CONCLUSIONS/INTERPRETATION: Overall, these data support the presence of a type 1 diabetes endotype associated with a genetic factor that predisposes to type 2 diabetes, with donors in this category exhibiting less severe beta cell loss. It is possible that in these individuals the disease pathogenesis may include mechanisms associated with type 2 diabetes and thus this may provide an explanation for the poor response to immunotherapies to prevent type 1 diabetes or its progression in a subset of individuals. If so, strategies that target both type 1 diabetes and type 2 diabetes-associated factors when they are present may increase the success of prevention and treatment in these individuals.
引用
- Redondo MJ, Richardson SJ, Perry D, et al. Milder loss of insulin-containing islets in individuals with type 1 diabetes and type 2 diabetes-associated TCF7L2 genetic variants. Diabetologia. 2022. PMID: 36282337. doi:10.1007/s00125-022-05818-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。